Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rucaparib - Clovis Oncology

Drug Profile

Rucaparib - Clovis Oncology

Alternative Names: AG-014699; AG-14699; CO-338; PF-01367338; PF-1367338; Rubraca; Rucaparib phosphate

Latest Information Update: 22 Feb 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cancer Research UK
  • Developer Bristol-Myers Squibb; Cancer Research UK; Clovis Oncology; Merck Sharp & Dohme; NHS Greater Glasgow and Clyde; Ohio State University Comprehensive Cancer Center; Roche; UNICANCER; University of California at San Francisco; University of Glasgow; University of Oklahoma; University of Utah
  • Class 3-ring heterocyclic compounds; Antineoplastics; Azepines; Indoles; Small molecules
  • Mechanism of Action Poly(ADP-ribose) polymerase 1 inhibitors; Poly(ADP-ribose) polymerase 2 inhibitors; Poly(ADP-ribose) polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Phase III Prostate cancer
  • Phase II Breast cancer; Cervical cancer; Endometrial cancer; Pancreatic cancer; Urogenital cancer
  • Phase I/II Non-small cell lung cancer
  • Phase I Gynaecological cancer; Solid tumours
  • Suspended Malignant melanoma

Most Recent Events

  • 19 Feb 2019 Clovis Oncology and Alkermes enter into R&D agreement to evaluate combination of rucaparib with ALKS 4230 and lucitanib
  • 15 Feb 2019 Hoffmann-La Roche plans a phase I/II trial for Beast, Ovarian or Prostate cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in the US, Australia, Italy, South Korea and Spain in March 2019 (NCT03840200)
  • 11 Feb 2019 Clovis Oncology plans the phase II ARIES trial in Ovarian cancer (Late-stage disease, Combination therapy), Urogenital cancer (Unresectable\Inoperable, Metastatic disease disease, Combination therapy) in February 2019 (NCT03824704)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top